## Lynn M Bekris

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3711203/publications.pdf Version: 2024-02-01



IVNN M REKDIS

#	Article	IF	CITATIONS
1	Peripheral sTREM2-Related Inflammatory Activity Alterations in Early-Stage Alzheimer's Disease. Journal of Immunology, 2022, 208, 2283-2299.	0.8	2
2	High-resolution functional connectivity of the default mode network in young adults with down syndrome. Brain Imaging and Behavior, 2021, 15, 2051-2060.	2.1	4
3	AlzGPS: a genome-wide positioning systems platform to catalyze multi-omics for Alzheimer's drug discovery. Alzheimer's Research and Therapy, 2021, 13, 24.	6.2	44
4	TNFRSF1B Gene Variants and Related Soluble TNFR2 Levels Impact Resilience in Alzheimer's Disease. Frontiers in Aging Neuroscience, 2021, 13, 638922.	3.4	7
5	Multimodal single-cell/nucleus RNA sequencing data analysis uncovers molecular networks between disease-associated microglia and astrocytes with implications for drug repurposing in Alzheimer's disease. Genome Research, 2021, 31, 1900-1912.	5.5	53
6	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	21.4	198
7	TREM2 alters the phagocytic, apoptotic and inflammatory response to Aβ42 in HMC3 cells. Molecular Immunology, 2021, 131, 171-179.	2.2	24
8	Unique Sleep and Circadian Rhythm Dysfunction Neuroinflammatory and Immune Profiles in Alzheimer's Disease with Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2021, 81, 487-492.	2.6	6
9	Temporal Ordering of Inflammatory Analytes sTNFR2 and sTREM2 in Relation to Alzheimer's Disease Biomarkers and Clinical Outcomes. Frontiers in Aging Neuroscience, 2021, 13, 676744.	3.4	11
10	Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing. Medicinal Research Reviews, 2020, 40, 2386-2426.	10.5	61
11	An Altered Relationship between Soluble TREM2 and Inflammatory Markers in Young Adults with Down Syndrome: A Preliminary Report. Journal of Immunology, 2020, 204, 1111-1118.	0.8	17
12	Inflammatory pathway analytes predicting rapid cognitive decline in MCI stage of Alzheimer's disease. Annals of Clinical and Translational Neurology, 2020, 7, 1225-1239.	3.7	19
13	Emerging blood-based biomarkers for Alzheimer disease. Cleveland Clinic Journal of Medicine, 2020, 87, 537-539.	1.3	1
14	Key inflammatory pathway activations in the MCI stage of Alzheimer's disease. Annals of Clinical and Translational Neurology, 2019, 6, 1248-1262.	3.7	38
15	Highly Elevated Cerebrospinal Fluid Total Tau Level Reflects Higher Likelihood of Non-Amnestic Subtype of Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 70, 1051-1058.	2.6	21
16	DNA methylation of TOMM40-APOE-APOC2 in Alzheimer's disease. Journal of Human Genetics, 2018, 63, 459-471.	2.3	57
17	Poly(ADP-ribose) drives pathologic α-synuclein neurodegeneration in Parkinson's disease. Science, 2018, 362, .	12.6	317
18	Regulation of ADAM10 by miR-140-5p and potential relevance for Alzheimer's disease. Neurobiology of Aging, 2018, 63, 110-119.	3.1	39

Lynn M Bekris

#	ARTICLE	IF	CITATIONS
19	Regulatory region genetic variation is associated with FYN expression in Alzheimer's disease. Neurobiology of Aging, 2017, 51, 43-53.	3.1	11
20	The APOE Gene is Differentially Methylated in Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 48, 745-755.	2.6	96
21	Cerebrospinal fluid Aβ <sub>42</sub> levels and <i>APP</i> processing pathway genes in Parkinson's disease. Movement Disorders, 2015, 30, 936-944.	3.9	14
22	The biomarker and therapeutic potential of miRNA in Alzheimer's disease. Neurodegenerative Disease Management, 2015, 5, 61-74.	2.2	49
23	The Spectrum of Mutations in Progranulin. Archives of Neurology, 2010, 67, 161-70.	4.5	166
24	Multiple SNPs Within and Surrounding the Apolipoprotein E Gene Influence Cerebrospinal Fluid Apolipoprotein E Protein Levels. Journal of Alzheimer's Disease, 2008, 13, 255-266.	2.6	75